Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation)
We present an updated analysis of lenvatinib in radioiodine-refractory differentiated thyroid cancer (RR-DTC) with new duration of response (DOR) data unavailable for the primary analysis. In this randomized, double-blind, multicenter, placebo-controlled phase 3 study, patients ≥18 years old with me...
Saved in:
Main Authors: | A. G. Gianoukakis, C. E. Dutcus, N. Batty, M. Guo, M. Baig |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2018-11-01
|
Series: | Опухоли головы и шеи |
Subjects: | |
Online Access: | https://ogsh.abvpress.ru/jour/article/view/361 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
by: M. S. Brose, et al.
Published: (2018-07-01) -
Observation and treatment of patients with progressive metastatic differentiated thyroid cancer after establishment of radioiodine refractoriness
by: E. V. Borodavina, et al.
Published: (2024-08-01) -
Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation
by: E. V. Borodavina, et al.
Published: (2020-04-01) -
Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice
by: P. O. Rumyantsev, et al.
Published: (2021-11-01) -
Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new?
by: E. V. Borodavina, et al.
Published: (2024-12-01)